ALLIANCE trial and the combinations of CYP17 and AR inhibitors in CRPC

Dr. Nima Sharifi, MD at Cleveland Clinic discusses the ALLIANCE trial and the combinations of CYP17 and AR inhibitors in CRPC at ASCO GU 2016 in San francisco

Advertisement Single Below Content

ALLIANCE trial and the combinations of CYP17 and AR inhibitors in CRPC

Advancing Acute Lymphoblastic Leukemia Treatment with CAR-T Cells: Insights from Dr. Anjali Advani

Advances in Acute Lymphoblastic Leukemia (ALL) Treatment: A Focus on Targeted Therapies – Elias Jabbour, MD

FDA grants accelerated approval to ponatinib (ICLUSIG®) with chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia

ALLIANCE trial and the combinations of CYP17 and AR inhibitors in CRPC

Related Posts

Advancing Acute Lymphoblastic Leukemia Treatment with CAR-T Cells: Insights from Dr. Anjali Advani

Advances in Acute Lymphoblastic Leukemia (ALL) Treatment: A Focus on Targeted Therapies – Elias Jabbour, MD

FDA grants accelerated approval to ponatinib (ICLUSIG®) with chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia